4//SEC Filing
Knight Therapeutics Inc 4
Accession 0001213900-25-054279
CIK 0001562733other
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 4:05 PM ET
Size
7.2 KB
Accession
0001213900-25-054279
Insider Transaction Report
Form 4
Knight Therapeutics Inc
10% Owner
Transactions
- Purchase
Pre-Funded Common Stock Purchase Warrant
2025-06-11+428,570→ 428,570 total(indirect: See footnote)→ Common Stock (428,570 underlying)
Footnotes (3)
- [F1]The Pre-Funded Common Stock Purchase Warrants (the "Warrants") are exercisable by the holder at any time on or after June 11, 2025 at an exercise price equal to $0.00001 per share, subject to adjustments as provided under the terms of the Warrant, subject to a post-exercise beneficial ownership limitation of 19.90% ("Beneficial Ownership Limitation").
- [F2]The Warrants will expire on June 11, 2026 with automatic extensions of one year each in case the Warrants have not been exercised in full due to the Beneficial Ownership Limitation.
- [F3]The 428,570 Warrants are held by Knight Therapeutics International S.A. ("Knight Subsidiary"), a wholly-owned subsidiary of the Reporting Person. The Reporting Person is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of the U.S. Securities Exchange Act of 1934 ("Act") of any securities of Issuer beneficially owned by Knight Subsidiary. The Reporting Person disclaims beneficial ownership over all of the securities beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for any other purpose.
Documents
Issuer
Synergy CHC Corp.
CIK 0001562733
Entity typeother
IncorporatedQuebec, Canada
Related Parties
1- filerCIK 0001756235
Filing Metadata
- Form type
- 4
- Filed
- Jun 12, 8:00 PM ET
- Accepted
- Jun 13, 4:05 PM ET
- Size
- 7.2 KB